A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Shigella sonnei vaccine GlaxoSmithKline (Primary) ; Shigella sonnei vaccine GlaxoSmithKline (Primary) ; Shigella sonnei vaccine GlaxoSmithKline (Primary)
- Indications Shigella infections
- Focus Adverse reactions
- Sponsors Novartis
- 05 Jan 2016 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 11 Dec 2014 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 11 Dec 2014 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.